ARDELYX, INC. Share-based Payment Arrangement, Expensed and Capitalized, Amount
ARDELYX, INC. (ARDX) reported Share-based Payment Arrangement, Expensed and Capitalized, Amount of $800.00 thousand for the 12-month period ending 2014-12-31, per its 10-K filed 2017-02-17.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1 · last filed 2017-02-17
- ARDELYX, INC. share-based payment arrangement, expensed and capitalized, amount for the quarter ending 2014-09-30 was $203.00K.
- ARDELYX, INC. share-based payment arrangement, expensed and capitalized, amount for fiscal 2014 was $800.00K.
| Period end | Share-based Payment Arrangement, Expensed and Capitalized, Amount 3 month | Share-based Payment Arrangement, Expensed and Capitalized, Amount 12 month |
|---|---|---|
| 2014-12-31 | $800.00K 10-K · filed 2017-02-17 | |
| 2014-09-30 | $203.00K 10-Q · filed 2014-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |